{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T12:08:29Z","timestamp":1774094909970,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012350","name":"British Liver Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary sclerosing cholangitis (PSC) is a rare incurable disease of the bile ducts and liver which can significantly impair quality of life (QoL). No existing QoL tools are entirely suitable for people living with PSC (PwPSC). We aimed to develop a measure of QoL for PwPSC in the UK, beginning by identifying relevant QoL issues. This paper describes our approach to this first stage, and discusses related benefits and limitations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Scientific consensus on how to reliably stage PSC is lacking, due to its rarity and heterogeneity. We initially hypothesised four categories for PSC severity. After beginning the study, these were revised to six. For such a rare disease, the study could not recruit sufficient participants in each of these categories, particularly the more severe, in the time available. We therefore modified the design, adapting standard methodology for identifying potentially relevant issues. We started by conducting a thematic analysis of data from a previous survey of PwPSC, and extracting QoL issues from a literature review of QoL questionnaires of relevance to PwPSC. We then conducted group and individual interviews with PwPSC and clinicians, investigating the relevance, importance, phrasing, and breadth of coverage of issues identified. We also explored the validity of our hypothesised categories for disease severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 1,052 potentially relevant QoL issues from the survey and literature review and took 396 of these forwards for discussion with 28 PwPSC. We found 168\/396 issues were considered relevant by \u2265\u200960% of these participants. We then discussed this subset of 168 issues with 11 clinicians. PSC and clinician participants identified some problematic phrasing with 19 issues, due to potential upset (n\u2009=\u200912) or problems with understanding (n\u2009=\u20097). We included one new issue from those suggested.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We identified a range of QoL issues relevant to PwPSC, with a good breadth of coverage, although lacking an in-depth understanding of the PSC experience. Our strategy effectively identified relevant QoL issues for people living with this rare condition, for which there is no consensus on stratifying for its severity. This strategy should however be considered specific to such circumstances, not a general recommendation for an alternative approach.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-022-00484-5","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:08:01Z","timestamp":1657904881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quality of life (QoL) for people with primary sclerosing cholangitis (PSC): a pragmatic strategy for identifying relevant QoL issues for rare disease"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-8976","authenticated-orcid":false,"given":"Elena","family":"Marcus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bella","family":"Vivat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"484_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/apt.12581","volume":"39","author":"TH Karlsen","year":"2014","unstructured":"Karlsen TH, Vesterhus M, Boberg KM (2014) Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther 39:282\u2013301. https:\/\/doi.org\/10.1111\/apt.12581","journal-title":"Aliment Pharmacol Ther"},{"key":"484_CR2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weismuller","year":"2017","unstructured":"Weismuller TJ et al (2017) Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 152:1975\u20131984. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.038","journal-title":"Gastroenterology"},{"key":"484_CR3","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","volume":"159","author":"PJ Trivedi","year":"2020","unstructured":"Trivedi PJ et al (2020) Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology 159:915\u2013928. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.049","journal-title":"Gastroenterology"},{"key":"484_CR4","doi-asserted-by":"publisher","first-page":"e7116","DOI":"10.1097\/MD.0000000000007116","volume":"96","author":"H Liang","year":"2017","unstructured":"Liang H, Manne S, Shick J, Lissoos T, Dolin P (2017) Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Medicine (Baltimore) 96:e7116. https:\/\/doi.org\/10.1097\/MD.0000000000007116","journal-title":"Medicine (Baltimore)"},{"key":"484_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317993","author":"MH Chapman","year":"2019","unstructured":"Chapman MH et al (2019) British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2018-317993","journal-title":"Gut"},{"key":"484_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/hep.28128","volume":"63","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi PJ, Corpechot C, Pares A, Hirschfield GM (2016) Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists. Hepatology 63:644\u2013659. https:\/\/doi.org\/10.1002\/hep.28128","journal-title":"Hepatology"},{"key":"484_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/flgastro-2017-100815","volume":"8","author":"K Arndtz","year":"2017","unstructured":"Arndtz K, Hirschfield GM (2017) Primary sclerosing cholangitis and the management of uncertainty and complexity. Frontline Gastroenterol 8:260\u2013266. https:\/\/doi.org\/10.1136\/flgastro-2017-100815","journal-title":"Frontline Gastroenterol"},{"key":"484_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s10620-015-4013-1","volume":"61","author":"AC Cheung","year":"2016","unstructured":"Cheung AC et al (2016) Factors that influence health-related quality of life in patients with primary sclerosing cholangitis. Dig Dis Sci 61:1692\u20131699. https:\/\/doi.org\/10.1007\/s10620-015-4013-1","journal-title":"Dig Dis Sci"},{"key":"484_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29775","author":"K Arndtz","year":"2018","unstructured":"Arndtz K, Hirschfield GM (2018) Quality of life and primary sclerosing cholangitis: the business of defining what counts. Hepatology. https:\/\/doi.org\/10.1002\/hep.29775","journal-title":"Hepatology"},{"key":"484_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01739-3","author":"E Marcus","year":"2021","unstructured":"Marcus E, Stone P, Krooupa AM, Thorburn D, Vivat B (2021) Quality of life in primary sclerosing cholangitis: a systematic review. Health Qual Life Outcomes. https:\/\/doi.org\/10.1186\/s12955-021-01739-3","journal-title":"Health Qual Life Outcomes"},{"key":"484_CR11","unstructured":"Marcus E (2020) Developing and pre-testing a measure of quality of life for people with primary sclerosing cholangitis (PSC) in the UK. Ph.D. Thesis, University College London."},{"key":"484_CR12","unstructured":"Johnson C et al. (2011) EORTC quality of life group module development guidelines, 4th edn. EORTC QL Group"},{"key":"484_CR13","doi-asserted-by":"publisher","first-page":"e12697","DOI":"10.1111\/ecc.12697","volume":"26","author":"B Vivat","year":"2017","unstructured":"Vivat B et al (2017) The international phase 4 validation study of the EORTC QLQ-SWB32: a stand-alone measure of spiritual well-being for people receiving palliative care for cancer. Eur J Cancer Care (Engl) 26:e12697. https:\/\/doi.org\/10.1111\/ecc.12697","journal-title":"Eur J Cancer Care (Engl)"},{"key":"484_CR14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K et al (2017) Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health 20:838\u2013855. https:\/\/doi.org\/10.1016\/j.jval.2017.05.015","journal-title":"Value Health"},{"key":"484_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40123-019-0188-4","volume":"8","author":"N Cook","year":"2019","unstructured":"Cook N et al (2019) Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Therapy 8:407\u2013420. https:\/\/doi.org\/10.1007\/s40123-019-0188-4","journal-title":"Ophthalmol Therapy"},{"key":"484_CR16","doi-asserted-by":"publisher","first-page":"e19232","DOI":"10.2196\/19232","volume":"21","author":"A Booth","year":"2019","unstructured":"Booth A et al (2019) Using social media to uncover treatment experiences and decisions in patients with acute myeloid leukemia or myelodysplastic syndrome who are ineligible for intensive chemotherapy: patient-centric qualitative data analysis. J Med Internet Res 21:e19232. https:\/\/doi.org\/10.2196\/19232","journal-title":"J Med Internet Res"},{"key":"484_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41687-017-0013-6","volume":"1","author":"L Humphrey","year":"2017","unstructured":"Humphrey L et al (2017) A comparison of three methods to generate a conceptual understanding of a disease based on the patients\u2019 perspective. J Patient Rep Outcomes 1:9. https:\/\/doi.org\/10.1186\/s41687-017-0013-6","journal-title":"J Patient Rep Outcomes"},{"key":"484_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2014.10.001","volume":"18","author":"M Rothman","year":"2015","unstructured":"Rothman M, Gnanaskathy A, Wicks P, Papadopoulos E (2015) Can we use social media to support content validity of patient-reported outcome instruments in medical product development? Value in Health 18:1\u20134. https:\/\/doi.org\/10.1016\/j.jval.2014.10.001","journal-title":"Value in Health"},{"key":"484_CR19","doi-asserted-by":"publisher","first-page":"A31","DOI":"10.1016\/S1098-3015(10)73216-2","volume":"12","author":"SL Acaster","year":"2009","unstructured":"Acaster SL, Wild D (2009) PMC65: a novel comparison of qualitative data sources: content analysis of semi-structured patient interviews versus weblogs. Value Health 12:A31","journal-title":"Value Health"},{"key":"484_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13023-017-0718-x","volume":"12","author":"T Morel","year":"2017","unstructured":"Morel T, Cano SJ (2017) Measuring what matters to rare disease patients\u2014reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis 12:171. https:\/\/doi.org\/10.1186\/s13023-017-0718-x","journal-title":"Orphanet J Rare Dis"},{"key":"484_CR21","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.ejca.2010.04.014","volume":"46","author":"C Johnson","year":"2010","unstructured":"Johnson C et al (2010) Development of the European organisation for research and treatment of cancer quality of life questionnaire module for older people with cancer: the EORTC QLQ-ELD15. Eur J Cancer 46:2242\u20132252. https:\/\/doi.org\/10.1016\/j.ejca.2010.04.014","journal-title":"Eur J Cancer"},{"key":"484_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/004912418101000205","volume":"10","author":"P Biernacki","year":"1981","unstructured":"Biernacki P, Waldorf D (1981) Snowball sampling: problems and techniques of chain referral sampling. Sociol Method Res 10:141\u2013163. https:\/\/doi.org\/10.1177\/004912418101000205","journal-title":"Sociol Method Res"},{"key":"484_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-021-01182-y","author":"D Byrne","year":"2021","unstructured":"Byrne D (2021) A worked example of Braun and Clarke\u2019s approach to reflexive thematic analysis. Qual Quant. https:\/\/doi.org\/10.1007\/s11135-021-01182-y","journal-title":"Qual Quant"},{"key":"484_CR24","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/ijerph15071342","volume":"15","author":"AD Keetharuth","year":"2018","unstructured":"Keetharuth AD et al (2018) Integrating qualitative and quantitative data in the development of outcome measures: the case of the recovering quality of life (ReQoL) measures in mental health populations. Int J Environ Res Public Health 15:1342. https:\/\/doi.org\/10.3390\/ijerph15071342","journal-title":"Int J Environ Res Public Health"},{"key":"484_CR25","first-page":"A13","volume":"2","author":"BC Choi","year":"2005","unstructured":"Choi BC, Pak AW (2005) A catalog of biases in questionnaires. Prev Chronic Dis 2:A13","journal-title":"Prev Chronic Dis"},{"key":"484_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199685219.001.0001","volume-title":"Health measurement scales: a practical guide to their development and use","author":"DL Streiner","year":"2015","unstructured":"Streiner DL, Norman GR, Cairney J (2015) Health measurement scales: a practical guide to their development and use, 5th edn. Oxford University Press","edition":"5"},{"key":"484_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/hep.28963","volume":"65","author":"EM de Vries","year":"2017","unstructured":"de Vries EM et al (2017) Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology 65:907\u2013919. https:\/\/doi.org\/10.1002\/hep.28963","journal-title":"Hepatology"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00484-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-022-00484-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00484-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:15:52Z","timestamp":1657905352000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-022-00484-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/s41687-022-00484-5","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the West London and GTAC Research Ethics Committee in August 2017 (reference number: 17\/LO\/1108). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author(s) declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}